Core Viewpoint - Kintor Pharmaceutical's stock has seen a significant increase following the approval of its new drug application for SKB105, a targeted antibody-drug conjugate for treating advanced solid tumors [1] Group 1: Company Developments - Kintor Pharmaceutical announced that its IND application for the self-developed targeted integrin β6 (ITGB6) antibody-drug conjugate (ADC) SKB105 (also known as CR-003) has been approved by the NMPA for clinical trials [1] - The company plans to submit an IND application for SKB118/CR-001, a bispecific antibody targeting PD-1 and VEGF, to the NMPA in the near future [1] Group 2: Strategic Partnerships - In December 2025, Kintor Pharmaceutical entered into a strategic collaboration with Crescent Biopharma, Inc. regarding SKB105/CR-003 and SKB118/CR-001 [1] - Under the agreement, Kintor grants Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105/CR-003 outside of Greater China, while Crescent grants Kintor exclusive rights for SKB118/CR-001 within Greater China [1]
港股异动 | 科伦博泰生物-B(06990)涨超6% ITGB6 ADC SKB105新药临床试验申请获批